The extraordinary increase in diabetes worldwide is a matter of great urgency. Molecular biology and genetic approaches have greatly advanced our understanding of the causes of diabetes and its complications and the development of treatment. Despite these advances, the average age at death of Japanese patients with diabetes is still over 10 years younger than the general population in Japan for the period 1971-2000, although the lifespan of both males and females with diabetes has lengthened with time in parallel with that of the Japanese population. The most frequent cause of death was malignant neoplasia, with vascular disease the second highest in frequency during the period 1991-2000. Moreover, recently it has been well recognized that the prevalence of dementia is higher in diabetic patients than non-diabetic subjects. As a possibility promoting cognitive decline in diabetic state, brain insulin resistance associated from defective insulin signaling is proposed in the recent studies. Coupled with the aging of society, an increase in the number of elderly diabetic patients is inevitable. Therefore, in addition to the prevention and the treatment of diabetes mellitus and its vascular complications, the best treatment for dementia in elderly diabetic patients will be one of the most important issues in diabetes management in the future. From these points of view, the management of diabetes and its related problems are discussed, including the effect of polyol pathway hyperactivity in the pathogenesis of diabetic complications.
The global epidemic of diabetes is a serious medical and social problem in all parts of the world including East and Southeast Asia, which have the highest prevalence of the disease. Type 2 diabetes in Asians is characterized primarily by pancreatic b cell dysfunction; the pathological manifestation in Europe and North America is generally insulin resistance with obesity. These differences have an immense impact on diabetes treatment in different populations.
The incretins GIP and GLP-1 are released from the gut in response to dietary nutrients and stimulate insulin secretion in a glucosedependent manner. Both GIP and GLP-1 are well-characterized in mice lacking receptors as well as in humans. Thus GLP-1 and GIP receptor agonists and DPP-4 inhibitors that enhance endogenous incretin activity have therapeutic implications in diabetes with b cell dysfunction. Earlier observations indicated that GLP-1 preserves its ability to stimulate insulin secretion in hyperglycemia while that of GIP is markedly reduced, which led to the development of the GLP-1 receptor agonists now in clinical use. However, accumulating evidence underscores the relevance of GIP.
In this lecture the biological importance of incretin hormones and the clinical potential of incretin-based therapies for Asian type 2 diabetes will be discussed. In addition, IDF-WPR's mission for prevention and management of diabetes will be examined by looking back to the years 2009-2012, in which IDF-WPR devoted significant efforts to projects such as the Asia-Pacific Congress of Diabetes Education and the IDF-WPR Foot Care Project to implement science-navigated diabetes education and care in the region.
